Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

about

Prostate cancer: the need for biomarkers and new therapeutic targets.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial Integrating Immunotherapies in Prostate Cancer.

P2860

Q37476043-3A0F95ED-0596-46D8-8E0D-C771DA45E34D Q37684364-2F9B0710-BF14-4CF1-AFAA-3767E554BAFA Q38567067-85856F7B-9451-4FB1-9A1C-91C8E732C0F4

P2860

Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

Item

http://www.wikidata.org/entity/Q37017101

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Therapeutic cancer vaccines in ...... ermediate markers of response.

@en

Therapeutic cancer vaccines in ...... ermediate markers of response.

@nl

type

Item

label

Therapeutic cancer vaccines in ...... ermediate markers of response.

@en

Therapeutic cancer vaccines in ...... ermediate markers of response.

@nl

prefLabel

Therapeutic cancer vaccines in ...... ermediate markers of response.

@en

Therapeutic cancer vaccines in ...... ermediate markers of response.

@nl

P1476

Therapeutic cancer vaccines in ...... termediate markers of response

@en

P2093

Christopher J Heery

http://www.w3.org/2001/XMLSchema#string

Joseph W Kim

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

ELISA and multiplex technologies for cytokine measurement in inflammation and aging research

Control of regulatory T cell development by the transcription factor Foxp3

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy

Phenotypic analysis of antigen-specific T lymphocytes

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

P304

1229-1246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS4041229

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marijo Bilusic

P577

2012-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258429977

http://www.w3.org/2001/XMLSchema#string

P698

24213505

http://www.w3.org/2001/XMLSchema#string

P932

3712729

http://www.w3.org/2001/XMLSchema#string

Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

about

P2860

P2860

Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932